14 completed, 10 unknown, 6 withdrawn, 3 not yet recruiting. 12 Phase 2, 10 Not applicable, 9 Phase 1, 5 Phase 3, 3 Phase 4.
Follow Stevens-Johnson Syndrome: new trials by email Literature Review of Stevens-Johnson Syndrome trials Research Report on Stevens-Johnson Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Withdrawn | Massachusetts General Hospital | 2030-01-01 | 2026-01-16 | ||
| Subconjunctival Humira for Boston Keratoprosthesis Adalimumab Injection - Penetrating Keratoplasty, Multiple Graft Failure | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 8 | 2026-10-01 | 2026-08-31 |
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. DARATUMUMAB (DARZALEX®) - Toxic Epidermal Necrolysis, Immunotherapy | Phase 1 / Phase 2 | Not yet recruiting | Hospices Civils de Lyon | 9 | 2025-10-29 | 2025-08-07 |
| Autologous Serum Obtained by a Closed-Circuit Collection Device Autologous Serum 20% - GVHD, Meibomian Gland Dysfunction (Disorder) | Phase 2 | Active not recruiting | GIANCARLO FATOBENE | 16 | 2025-06-20 | 2026-10-21 |
| LYell SYndrome MEsenchymal Stromal Cells Treatment Adipose derived stromal cells intravenously injected - Epidermal Necrolysis, Lyell Syndrome | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 15 | 2024-04-15 | 2025-08-01 |
| Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis Abrocitinib, Tofacitinib - Toxic Epidermal Necrolysis | Early Phase 1 | Unknown | Peng Zhang | 30 | 2023-07-05 | 2023-11-28 |
| NATIENS: Optimal Management and Mechanisms of SJS/TEN Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4 - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Phase 3 | Completed | Vanderbilt University Medical Center | 2 | 2023-03-21 | 2025-12-17 |
| Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome | Phase 1 / Phase 2 | Unknown | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 20 | 2022-11-11 | 2024-07-08 |
| Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN Tofacitinib - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis | Not applicable | Completed | Chang Gung Memorial Hospital | 20 | 2022-08-01 | 2025-09-16 |
| Severe Bullous Drug Eruption and Filgrastim Filgrastim, Placebo - Rare Diseases, Toxic Epidermal Necrolyses | Phase 2 / Phase 3 | Unknown | Hospices Civils de Lyon | 42 | 2022-05-13 | 2024-05-08 |
| Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Maskin Probe - Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses | Not applicable | Unknown | Massachusetts Eye and Ear Infirmary | 30 | 2021-12-01 | 2021-12-06 |
| Vitamin D Levels in Non-immediate Drug Hypersensitivity Case-control Study Stevens-Johnson Syndrome, Drug Reaction With Eosinophilia and Systemic Symptom | Completed | Chulalongkorn University | 120 | 2021-05-30 | 2024-02-16 | |
| Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease Tangible Boost, Placebo - Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye | Not applicable | Terminated | Tangible Science | 28 | 2020-02-24 | 2025-09-16 |
| Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Stevens-Johnson Syndrome, Lyell Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 500 | 2018-09-26 | 2022-05-03 | |
| HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions HLA screening before commencing aromatic AEDs - Epilepsy, Neuropathy | Not applicable | Unknown | Second Affiliated Hospital of Guangzhou Medical University | 4000 | 2017-08-01 | 2018-09-05 |
| Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population A single blood sample for HLA typing - Pemphigus, Bullous Pemphigoid | Unknown | Sechenov University | 120 | 2017-05-17 | 2022-03-17 | |
| Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Clobetasol 0.05% ointment, Placebo - Toxic Epidermal Necrolysis | Phase 1 / Phase 2 | Withdrawn | University of California, Davis | 2016-11-01 | 2019-08-09 | |
| Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Isotretinoin, Placebo - Toxic Epidermal Necrolysis | Not applicable | Withdrawn | Massachusetts General Hospital | 2016-11-01 | 2023-06-07 | |
| Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis minor salivary gland transplantation - Cicatrizing Conjunctivitis, Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | Not applicable | Unknown | National Taiwan University Hospital | 30 | 2016-09-01 | 2019-02-15 |
Showing 20 of 40. Sign in to see all of them.
Dry Eye Syndromes (5) · Pemphigoid, Benign Mucous Membrane (5) · Drug-Related Side Effects and Adverse Reactions (4) · Aniridia (2) · Autoimmune Diseases (2) · Burns, Chemical (2) · Drug Eruptions (2) · Drug Hypersensitivity (2) · Drug Hypersensitivity Syndrome (2) · Graft vs Host Disease (2) · Limbal Stem Cell Deficiency (2) · Meibomian Gland Dysfunction (2) · Pemphigoid, Bullous (2) · Pterygium (2)
Chemically-Induced Disorders (40) · Dermatitis (40) · Erythema (40) · Hypersensitivity (40) · Hypersensitivity, Delayed (40) · Immune System Diseases (40) · Mouth Diseases (40) · Skin Diseases (40) · Skin Diseases, Vesiculobullous (40) · Skin and Connective Tissue Diseases (40) · Stomatitis (40) · Stomatognathic Diseases (40) · Erythema Multiforme (39) · Drug Eruptions (38) · Drug Hypersensitivity (38)
Infliximab (3) · Filgrastim (2) · tofacitinib (2) · Adalimumab (1) · Allopurinol (1) · Clobetasol (1) · Cyclosporine (1) · Etanercept (1) · Febuxostat (1) · Fibroblast Growth Factor 7 (1) · Histocompatibility Testing (1) · Immunoglobulins, Intravenous (1) · Isotretinoin (1) · Lamotrigine (1) · Methylprednisolone Hemisuccinate (1)
Massachusetts Eye and Ear Infirmary (3) · Assistance Publique - Hôpitaux de Paris (2) · Chulalongkorn University (2) · Hospices Civils de Lyon (2) · Mahidol University (2) · Massachusetts General Hospital (2) · Seoul National University Hospital (2) · Brett King (1) · Centre Hospitalier Universitaire Vaudois (1) · Chang Gung Memorial Hospital (1) · Chao Ji (1) · Federal University of São Paulo (1) · GIANCARLO FATOBENE (1) · George Washington University (1) · Haiphong University of Medicine and Pharmacy (1)
United States (11) · France (4) · Thailand (4) · Brazil (3) · China (3) · Belgium (2) · South Korea (2) · Taiwan (2) · Canada (1) · Germany (1) · Japan (1) · Russia (1) · Singapore (1) · Spain (1)
James Chodosh, MD, MPH (2) · Pinnita Prabhasawat, MD (2) · Arturo Saavedra, MD, PhD (1) · Carina Koppen, MD, PhD (1) · Chun Bing Chen (1) · Claes H Dohlman, MD, PhD (1) · Donald T Tan, FRCS (1) · Eckert Philippe, MD (1) · Edwaldo Dr Dourado, Doctor (1) · Elizabeth J Phillips, MD (1) · Emanual Maverakis, MD (1) · Hsiao-Sang Chu, MD, MS (1) · Jettanong Klaewsongkram, MD (1) · Joseph Ciolino, MD (1)
PMID 12558848, PMID 15161841, PMID 15287367, PMID 26297574, PMID 27106261, PMID 28476287, PMID 29478292, PMID 29800753, PMID 30346532, PMID 34734507, PMID 37086614, PMID 37678574